Company performance
Add to research
Current Price
as of Apr 11, 2025$26.20
P/E Ratio
N/A
Market Cap
$10.11B
Loading...
Description
Add to research
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Metrics
Add to research
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerMRNA
- Price$26.2+6.94%
Trading Information
- Market cap$10.11B
- Float88.55%
- Average Daily Volume (1m)10,151,936
- Average Daily Volume (3m)11,484,987
- EPS-$9.27
Company
- Revenue$3.24B
- Rev growth (1yr)-52.69%
- Net income-$3.56B
- Gross margin48.92%
- EBITDA margin-116.07%
- EBITDA-$3.76B
- EV$9.69B
- EV/Revenue2.99
- P/EN/A
- P/S3.11
- P/B0.93
- Debt/Equity6.85
Documents
Add to research
SEC Filings
Earnings Calls
Factset Street Account
Wikipedia